Preclinical evaluation of PNU-151774E as a novel anticonvulsant

Journal of Pharmacology and Experimental Therapeutics

Volumn 285, Issue 2, 1998, Pages 397-403

  Fariello, R G ^a,b   McArthur, R A ^c   Bonsignori, A ^c   Cervini, M A ^c   Maj, R ^c   Marrari, P ^d   Pevarello, P ^c   Wolf, H H ^a   Woodhead, J W ^e   White, H S ^e   Varasi, M ^c   Salvati, P ^c   Post, C ^c  

^a Istituti Clinici di Perfezionamento ^*

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c PFIZER INC   (United States)

^d Pharmacokin/Metab PUSpA   (Italy)

^e UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (3 FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDE METHANESULFONATE; 3 MERCAPTOPROPIONIC ACID; ANTICONVULSIVE AGENT; BICUCULLINE; CARBAMAZEPINE; DIAZEPAM; DIZOCILPINE; LAMOTRIGINE; MESYLIC ACID DERIVATIVE; MONOAMINE OXIDASE B INHIBITOR; PENTETRAZOLE; PHENOBARBITAL; PHENYTOIN; PICROTOXIN; SAFINAMIDE; SODIUM CHANNEL BLOCKING AGENT; STRYCHNINE; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; ATAXIA; COGNITIVE DEFECT; CONVULSION; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; DRUG TOLERANCE; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LOCOMOTION; MALE; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PASSIVE AVOIDANCE; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ALANINE; ANIMALS; ANTICONVULSANTS; AVOIDANCE LEARNING; BENZYLAMINES; DRUG TOLERANCE; MALE; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR;

EID: 7144229372     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Baulac M, Arzimanoglou A, Semah A and Cavalcanti D (1997) Therapeutic options provided by new antiepileptic drugs. Rev Neurol (Parts) 155:21-33.
2. Beghi E and Perucca E (1995) The management of epilepsy in the 1990's. Acquisitions, uncertainties and priorities for future research. Drugs 49:680-694.
3. Besag FM Wallace SJ, Dulac O, Alving J, Spencer SC and Hosking G (1995) Lamotrigine for the treatment of epilepsy in childhood. J Pediatr 127:991-997.
4. Ben-Ari Y (1985) Limbic seizure and brain damage produced by kainic acid: Mechanisms and relevance to human temporal lobe epilepsy. Neuroscience 14:375-403.
5. Binnie CD (1994) Cognitive impairment-is it inevitable? Seizure 3: suppl A, 17-21.
6. Bouman WP, Pinner G and Johnson H (1997) Cognitive impairment associated with lamotrigine. Br J Psychiatry 170:388-389.
7. Brodie MJ and Dichter MA (1996) Antiepileptic drugs. N Engl J Med 334:168-175.
8. Browning RA (1987) Effects of lesions on seizures in experimental animals, in Epilepsy and the Reticular Formation: The Role of the Reticular Core in Convulsive Seizures (Fromm GH, Faingold CL, Browning RA and Burnham WM, eds) pp 137-162. Alan R. Liss, New York.
9. Chadwick D (1994) Standard approach to antiepileptic drug treatment in the United Kingdom. Epilepsia 35: suppl 4, S3-S10.
10. Cohen AF, Ashby L, Crowley D, Land G, Peck AW and Miller AA (1985) Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with phenytoin and diazepam. Br J Clin Pharmacol 20:619-629.
11. Ferrie CD, Robinson RO, Knott C and Panayiotopoulos CP (1995) Lamotrigine as an add-on drug in typical absence seizures. Acta Neurol Scand 91:200-202.
12. Finney DJ (19641) Probit Analysis, Cambridge University Press, Cambridge.
13. Fromm GH (1987) The brainstem and seizures: Summary and synthesis, in Epilepsy and the Reticular Formation: The Role of the Reticular Core in Convulsive Seizures (Fromm GH, Faingold CL, Browning RA and Burnham WM, eds) pp 203-218, Alan R. Liss, New York.
14. Gastaut H, Gastaut JL, Goncalves e Silva GE and Fernandez Sanchez GR (1975) Relative frequency of different types of epilepsy: a study employing the classification of epileptic seizures. Epilepsia 16:457-461.
15. Gillham R, Baker G, Thompson P, Birbeck K, McGuire A, Tomlinson L, Eckersley L, Silveira C and Brown S (1996) Standardisation of a self-report questionnaire for use in evaluating cognitive, affective and behavioural side-effects of anti-epileptic drug treatments. Epilepsy Res 24:47-55.
16. Goa KL, Ross SR and Chrisp P (1993) Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 46:152-176.
17. Kälviäinen R, Äikiä M and Riekkinen PJ Sr (1996) Cognitive adverse effects of antiepileptic drugs. Incidence, mechanisms and therapeutic implications. CNS Drugs 5:358-368.
18. Kirk RE (1968) Experimental Design: Procedures for the Behavioral Sciences, Brooks-Cole Publishing Company, Belmont, CA.
19. Loscher W and Lehmann H (1996) L-deprynyl (selegiline) exerts anticonvulsant effects against different seizure typed in mice. J Pharmacol Exp Ther 277:1410-1417.
20. Loscher W, Dagmar H, Fassbender CP and Nolting B (1991) The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. PentyIenetetrazole seizure models. Epilepsy Res 8:171-189.
21. Macdonald RL and Kelly KM (1993) Antiepileptic drug mechanisms of action. Epilepsia 34:S1-S8.
22. McNamara JO, Byrne MC, Dasheiff RM and Fitz JG (1980) The kindling model of epilepsy: A review. Prog Neurobiol 15:139-159.
23. Maj R, Antongiovanni V, Bonsignori A, Breda M, Dostert P, Fariello RG, McArthur RA, Varasi M and Bianchetti A (1993) Anticonvulsant profile of benzylaminopropanamide derivatives in mice and rain. Paper read at Focus on Epilepsy II, an International Conference, Whistler, B.C., Canada, September 11-14, 1993.
24. Maj R, Breda M, Antongiovanni V, Bonsignori A, Varasi M and McArthur RA (1995) Anticonvulsant activity of FCE 26743 in the kindling model of epilepsy. Pharmacol Res 31: suppl. 346.
25. Maj R, Fariello RG, Breda M, Pevarello P, Ukmar G, McArthur RA and Salvati P (1996) PNU-151774 (FCE 26743) protects against kainate-induced status epilepticus and neuronal damage in rats. Eur J Neurosci Suppl 9, 209.
26. Mattson RH (1992) Drug treatment of uncontrolled seizures. Epilepsy Res 5: suppl, 29-35.
27. Miller AA, Wheatley P, Sawyer DA, Baxter MG and Roth B (1986) Pharmacological studies on lamotrigine, a novel potential antiepileptic drug. 1. Anticonvulsant profile in mice and rats. Epilepsia 27:483-489.
28. Morselli PL (1995) Carbamazepine: Absorption, distribution, and excretion, in Antiepileptic Drugs (Levy RH, Mattson RH and Meldrum BS, eds) 4th ed, pp 515-528, Raven Press, Ltd., New York.
29. Parsons DN, Dickens M and Morley TJ (1995) Lamotrigine: Absorption, distribution, and excretion, in Antiepileptic Drugs (Levy RH, Mattson RH and Meldrum BS, eds) 4th ed, pp 877-881, Raven Press, Ltd., New York.
30. Pellock JM (1994) Standard approach to antiepileptic drug treatment in the United States. Epilepsia 35: suppl 4, S11-S18.
31. Pevarello P, Bonsignori A, Caccia C, Fornaretto MG, Salvati P and Varasi M (1996) Stereoselectivity, sigma binding and sodium channel blocking activity of 2-aminopropanamide anticonvulsants. Paper read at the XIVth Symposium on Medicinal Chemistry, Maastricht, The Netherlands, September 12-15, 1996.
32. Pevarello P, Bonsignori A, Dostert P, Heidempergher F, Pinciroli V, Colombo M, McArthur RA, Salvati P, Post C, Fariello RG, and Varasi M (1998) Synthesis and anticonvulsant activity of a new class of 2-[(arylalkyl)amino]alkanamide derivatives. J Med Chem 41:579-590.
33. Piredda S and Gale K (1985) A crucial epileptic site in the deep prepyriform cortex. Nature 317:623-625.
34. Pirreda SG, Woodhend JH and Swinyard EA (1985) Effect of stimulus intensity on the profile of anticonvulsant activity of phenytoin, ethosuximide and valproate. J Pharmacol Exp Ther 232:744-745.
35. Pranzatelli MR and Nadi NS (1995) Mechanism of action of antiepileptic and antimyoclonic drugs. Adv Neurol 67:329-360.
36. Schmidt D, Kupferberg HJ, Yonekawa W and Penry JK (1980.) The development of tolerance to the anticonvulsant effect of phenobarbital in mice. Epilepsia 21:141-147.
37. Shorvon SD (1990) Epidemiology, classification, natural history, and genetics of epilepsy. Lancet 336:93-96.
38. Strolin-Benedetti M, Marrari P, Colombo M, Castelli MG, Arand M, Oesch F and Dostert P (1994) The anticonvulsant FCE 26743 is a selective and short-acting MAO-B inhibitor devoid of inducing properties towards cytochrome P450-dependent testosterone hydroxylation in mice and rata. J Pharm Pharmacol 46:814-819.
39. Treiman DM and Woodbury DM (1995) Phenytoin: Absorption, distribution, and excretion, in Antiepileptic Drugs (Levy RH, Mattson RH and Meldrum BS, eds) 4th ed, pp 301-314. Raven Press, Ltd., New York.
40. Trimble MR and Cull C (1988) Children of school age: The influence of antiepileptic drugs on behavior and intellect. Epilepsia 29:S15-S19.
41. Vaghi F, Maj R, Rosa B, Ukmar G, Lamberti E, McArthur RA, Varasi M, Salvati P and Post C (1997) Neuroprotective effect of PNU-151774E, a new anticonvulsant compound, in the model of global ischaemia in gerbils. Soc Neurosci Abstr 23:545.
42. van Rijn CM, Weyn Banningh EW and Coenen AM (1994) Effects of lamotrigine on absence seizures in rats. Pol J Pharmacol 46:467-470.
43. White HS, Woodhead JH, Franklin MR, Swinyard EA and Wolf HH (1995a) General Principles: Experimental selection, quantification, and evaluation of antiepileptic drugs, in Antiepileptic Drugs (Levy RH, Mattson RH and Meldrum BS, eds) 4th ed, pp 99-110, Raven Press, Ltd., New York.
44. White HS, Johnson M, Wolf HH and Kupfenberg HG. (1995b) The early identification of anticonvulsant activity: Role of the maximal electroshock and subcutaneous pentylenetetrazole seizure models. Ital J Neurol Sci 16:73-77.